Erbitux®

DRUG4 trials

Sponsors

University of Heidelberg Medical Center, R-Pharm, Taizhou Mabtech Pharmaceutical Co.,Ltd

Conditions

Colorectal CancerHead and Neck CancerHead and Neck Squamous Cell Carcinoma

Phase 1

A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

CompletedNCT07435311

R-PharmHead and Neck Squamous Cell Carcinoma

Start: 2020-06-15End: 2024-07-17Updated: 2026-02-27

Phase 3

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Active, not recruitingNCT07435324

R-PharmHead and Neck Squamous Cell Carcinoma

Start: 2024-08-08End: 2026-06-21Updated: 2026-02-27

Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.

Not yet recruitingNCT07595276

Taizhou Mabtech Pharmaceutical Co.,LtdColorectal Cancer

Start: 2026-06-01End: 2030-06-01Target: 608Updated: 2026-05-19

Phase 4

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)

CompletedNCT01553032

University of Heidelberg Medical CenterHead and Neck Cancer

Start: 2011-06-30End: 2017-05-31Updated: 2022-05-25

Related Papers

Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.

2013-07-157 citations